This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Paratek Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Paratek Pharmaceuticals' CEO is Evan Loh, appointed in Jun 2019, has a tenure of 4.25 years. total yearly compensation is $2.04M, comprised of 31.8% salary and 68.2% bonuses, including company stock and options. directly owns 1.87% of the company’s shares, worth $2.38M. The average tenure of the management team and the board of directors is 4.3 years and 8.9 years respectively.
Informazioni chiave
Evan Loh
Amministratore delegato
US$2.0m
Compenso totale
| Percentuale dello stipendio del CEO | 31.8% |
| Mandato del CEO | 4.3yrs |
| Proprietà del CEO | 1.9% |
| Durata media del management | 4.3yrs |
| Durata media del Consiglio di amministrazione | 8.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$63m |
| Mar 31 2023 | n/a | n/a | -US$66m |
| Dec 31 2022 | US$2m | US$650k | -US$64m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$86m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$4m | US$600k | -US$59m |
| Sep 30 2021 | n/a | n/a | -US$52m |
| Jun 30 2021 | n/a | n/a | -US$54m |
| Mar 31 2021 | n/a | n/a | -US$87m |
| Dec 31 2020 | US$2m | US$575k | -US$97m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$111m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$2m | US$520k | -US$129m |
| Sep 30 2019 | n/a | n/a | -US$124m |
| Jun 30 2019 | n/a | n/a | -US$124m |
| Mar 31 2019 | n/a | n/a | -US$120m |
| Dec 31 2018 | US$2m | US$480k | -US$112m |
| Sep 30 2018 | n/a | n/a | -US$111m |
| Jun 30 2018 | n/a | n/a | -US$101m |
| Mar 31 2018 | n/a | n/a | -US$89m |
| Dec 31 2017 | US$3m | US$450k | -US$89m |
| Sep 30 2017 | n/a | n/a | -US$94m |
| Jun 30 2017 | n/a | n/a | -US$96m |
| Mar 31 2017 | n/a | n/a | -US$108m |
| Dec 31 2016 | US$1m | US$415k | -US$112m |
Compensazione vs Mercato: Evan's total compensation ($USD2.04M) is above average for companies of similar size in the US market ($USD764.66K).
Compensazione vs guadagni: Evan's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Evan Loh (64 yo)
4.3yrs
Mandato
US$2,042,511
Compensazione
Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh served as Independent Director at Windtree Therapeutics, Inc. since Februa...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 8.9yrs | US$1.73m | 1.93% $ 2.5m | |
| CEO & Director | 4.3yrs | US$2.04m | 1.87% $ 2.4m | |
| President & Chief Commercial Officer | 4.3yrs | US$1.15m | 1.09% $ 1.4m | |
| VP of Finance | 8.5yrs | Nessun dato | Nessun dato | |
| Senior VP | 8.3yrs | US$1.25m | 0.62% $ 797.8k | |
| Deputy General Counsel & Chief Compliance Officer | 6.1yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 4.2yrs | Nessun dato | Nessun dato | |
| Chief Development & Regulatory Officer | 4.3yrs | Nessun dato | 0.58% $ 735.2k |
4.3yrs
Durata media
58.5yo
Età media
Gestione esperta: PRTK's management team is considered experienced (4.3 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 8.9yrs | US$1.73m | 1.93% $ 2.5m | |
| CEO & Director | 11.3yrs | US$2.04m | 1.87% $ 2.4m | |
| Lead Independent Director | 8.9yrs | US$147.80k | 0.097% $ 124.0k | |
| Independent Outside Director | 8.9yrs | US$150.30k | 0.087% $ 111.5k | |
| Independent Outside Director | 7.5yrs | US$137.80k | 0.10% $ 131.6k | |
| Independent Outside Director | 8.2yrs | US$135.30k | 0.10% $ 131.6k | |
| Independent Outside Director | 8.9yrs | US$140.30k | 0.091% $ 116.5k | |
| Independent Director | 5.4yrs | US$127.80k | 0.11% $ 142.7k | |
| Independent Director | 2.3yrs | US$132.80k | 0.068% $ 87.4k |
8.9yrs
Durata media
64yo
Età media
Consiglio di amministrazione esperto: PRTK's board of directors are considered experienced (8.9 years average tenure).